Merck & Co., Inc. (MSD) (NYSE: MRK) announced that its hypoxia‑inducible factor 2α (HIF‑2α) inhibitor Welireg (belzutifan tablets) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adolescent (aged 12 and older) and adult patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) – marking the drug’s second approved indication in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New indication – marketing approval |
| Product | Welireg (belzutifan tablets), oral |
| Indication | Locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) |
| Population | Adolescents aged 12 and older and adults |
| Approval Date | 22 Oct 2026 |
| Prior China Approval | Nov 2024 – VHL disease‑associated RCC, CNS hemangioblastomas, and pNET not requiring immediate surgery (adults) |
| Mechanism Class | First‑in‑class HIF‑2α inhibitor |
Drug Profile & Mechanism of Action
- Molecule: Belzutifan – an oral, first‑in‑class hypoxia‑inducible factor 2α (HIF‑2α) inhibitor administered as tablets.
- Target & Biology: HIF‑2α is a transcription factor driving the pseudohypoxic signaling central to tumors with VHL pathway dysregulation; inhibiting it downregulates downstream oncogenic and angiogenic programs.
- PPGL Rationale: Pheochromocytomas and paragangliomas are rare neuroendocrine tumors of the adrenal gland and extra‑adrenal paraganglia, frequently driven by pseudohypoxia‑cluster genetic alterations (including VHL, SDHx) – making HIF‑2α blockade a mechanistically targeted approach for advanced, unresectable disease.
- Adolescent Inclusion: The approval extends to patients aged 12 and older, addressing a rare‑tumor population where hereditary PPGL syndromes often present early and systemic options are scarce.
- Chinese Label History: Belzutifan was first approved in China in November 2024 for adult patients with von Hippel‑Lindau (VHL) disease‑associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET) not requiring immediate surgery.
Disease Landscape & Clinical Position
| Item | Detail |
|---|---|
| Disease | Pheochromocytoma / paraganglioma (PPGL) – rare neuroendocrine tumors |
| Setting | Locally advanced, unresectable, or metastatic |
| Prior Systemic Options in China | Limited; largely chemotherapy‑based or off‑label |
| Belzutifan Evidence Package | Specific supporting trial data not disclosed in the announcement |
For patients with metastatic or unresectable PPGL, treatment options have historically been confined to cytotoxic chemotherapy, radionuclide therapy and clinical trials; the arrival of a targeted oral HIF‑2α inhibitor introduces a mechanistically rational, pill‑based alternative in a rare‑disease space with high unmet need.
Market Impact & Outlook
- Rare‑Disease Franchise Building: The PPGL approval gives Merck a second China indication for belzutifan within two years, compounding its rare‑oncology footprint across VHL‑associated tumors and now sporadic/hereditary PPGL.
- Orphan Advantage: PPGL affects a small patient population but carries high disease burden and few approved therapies – supporting potential orphan‑drug positioning, pricing stability and clinician adoption in specialized centers.
- Pediatric Access: Inclusion of adolescents from age 12 broadens the addressable population in hereditary PPGL syndromes, where early‑onset disease is common.
- Mechanism Validation: Each new HIF‑2α‑driven indication reinforces belzutifan’s platform value and may support exploration of additional pseudohypoxia‑cluster tumors.
- Next Milestones: Commercial launch and specialist‑center access in China; potential label expansion. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market uptake, reimbursement access, and further development of Welireg (belzutifan) in China. Actual results may differ materially due to risks including rare‑disease market adoption, pricing and reimbursement policy, safety signals in broader use, and competitive dynamics.-Fineline Info & Tech
